MGD013 dual-affinity re-targeting (DART) Uses, Dosage, Side Effects and more
MGD013 dual-affinity re-targeting (DART) is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
| Trade Name | MGD013 dual-affinity re-targeting (DART) |
| Generic | Tebotelimab |
| Tebotelimab Other Names | MGD013 dual-affinity re-targeting (DART) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
